Overactive Bladder clinical trials at UC Irvine
3 research studies open to eligible people
BlueWind RENOVA iStim™ System for the Treatment of OAB
open to eligible females ages 18-80
The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibial neuromodulation System for the treatment of patients diagnosed with overactive bladder.
Orange, California and other locations
CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology
open to eligible people ages 18 years and up
This is a prospective, randomized, controlled, multi-center, study in which 150 evaluable subjects will be randomized 1:1 to receive either a Protect CAN-Stim or SNS InterStim® system. Subjects from both groups will immediately start with therapy. The primary endpoint is a ≥ 50% reduction in number of incontinence episodes associated with urgency at the 3-month visit, with additional measurements assessed at 14 days, 1, 6, 9 and 12-months.
Orange, California and other locations
Intradetrusor Botulinum Toxin A: Are Less Injections Better?
open to eligible females ages 18 years and up
Patients with either overactive bladder (OAB) or urgency urinary incontinence (UUI) with be randomized (like a flip of a coin) to receive 100 units of bladder Botox® at either one injection site or ten injection sites. Efficacy and patient satisfaction will be measured by questionnaires.
Orange, California
Our lead scientists for Overactive Bladder research studies include Felicia Lane, MD.
Last updated: